Delve

Delve Bio is a San Francisco-based diagnostic company specializing in metagenomic next-generation sequencing (mNGS) to identify infectious diseases. Spun out of the University of California, San Francisco (UCSF), the company's platform, DelveDetect, enables the unbiased detection of bacteria, viruses, fungi, and parasites from a single clinical sample. By leveraging advanced sequencing and proprietary bioinformatics, Delve Bio aims to provide definitive diagnoses for complex clinical cases, such as meningitis and encephalitis, where traditional testing often fails. The company is backed by prominent investors including GV and Section 32 and is currently expanding its testing menu to include sepsis and respiratory infections.